Joyce W Hoot1, Li Wang2, Terry Kho3, Oleg E Akilov1. 1. a Department of Dermatology , University of Pittsburgh , Pittsburgh , PA , USA. 2. b Clinical and Translational Science Institute , University of Pittsburgh , Pittsburgh , PA , USA. 3. c University of Pittsburgh School of Medicine , Pittsburgh , PA , USA.
Abstract
BACKGROUND: Phototherapy has been a mainstay in the treatment of mycosis fungoides (MF). However, the recent findings of UV-induced p53 mutations in advanced MF suggest that phototherapy may contribute to disease progression. OBJECTIVE: The objective of this study was to evaluate the effect of phototherapy on the time to tumor progression and overall survival in MF. MATERIALS AND METHODS: Retrospective analysis of patients seen at the University of Pittsburgh Cutaneous Lymphoma Clinic from 1979 to 2016. RESULTS: A total of 345 patients with MF were identified. 258 (74.8%) were diagnosed at stage IA or IB. 43 out of the 258 (16.6%) progressed to tumor stage. Before tumor development, 30 out of the 43 (69.8%) patients received phototherapy, and 13 (30.2%) did not. Patients who received phototherapy had a longer median time to tumor progression than those who did not: 3.5 years (interquartile range = 1.9-5.7) versus 1.2 years (0.2-2.3) (p = .001). Patients who received phototherapy also survived longer: 6.9 years (interquartile range = 4.3-9.5) versus 3.8 years (3.0-4.5) (p = .014). LIMITATIONS: Limited information on specific phototherapy start dates, durations, and treatment protocols. CONCLUSIONS: The therapeutic effects of phototherapy, with longer times to tumor progression and increased overall survival, appear to outweigh its potential adverse effects.
BACKGROUND: Phototherapy has been a mainstay in the treatment of mycosis fungoides (MF). However, the recent findings of UV-induced p53 mutations in advanced MF suggest that phototherapy may contribute to disease progression. OBJECTIVE: The objective of this study was to evaluate the effect of phototherapy on the time to tumor progression and overall survival in MF. MATERIALS AND METHODS: Retrospective analysis of patients seen at the University of Pittsburgh Cutaneous Lymphoma Clinic from 1979 to 2016. RESULTS: A total of 345 patients with MF were identified. 258 (74.8%) were diagnosed at stage IA or IB. 43 out of the 258 (16.6%) progressed to tumor stage. Before tumor development, 30 out of the 43 (69.8%) patients received phototherapy, and 13 (30.2%) did not. Patients who received phototherapy had a longer median time to tumor progression than those who did not: 3.5 years (interquartile range = 1.9-5.7) versus 1.2 years (0.2-2.3) (p = .001). Patients who received phototherapy also survived longer: 6.9 years (interquartile range = 4.3-9.5) versus 3.8 years (3.0-4.5) (p = .014). LIMITATIONS: Limited information on specific phototherapy start dates, durations, and treatment protocols. CONCLUSIONS: The therapeutic effects of phototherapy, with longer times to tumor progression and increased overall survival, appear to outweigh its potential adverse effects.
Entities:
Keywords:
Mycosis fungoides; NB UVB; PUVA; cutaneous T-cell lymphoma; phototherapy; rate of progression; tumor stage
Authors: Patrik L Ståhl; Henrik Stranneheim; Anna Asplund; Lisa Berglund; Fredrik Pontén; Joakim Lundeberg Journal: J Invest Dermatol Date: 2010-10-14 Impact factor: 8.551
Authors: Lorraine Tracey; Raquel Villuendas; Ana Maria Dotor; Inmaculada Spiteri; Pablo Ortiz; Juan F Garcia; Jose Luis Rodriguez Peralto; Mark Lawler; Miguel A Piris Journal: Blood Date: 2003-04-10 Impact factor: 22.113
Authors: Christiane Querfeld; Steven T Rosen; Timothy M Kuzel; Katharine A Kirby; Henry H Roenigk; Bettina M Prinz; Joan Guitart Journal: Arch Dermatol Date: 2005-03